Drug Profile
Gallium-68 P16 093
Alternative Names: [68Ga]P16-093; Ga-68 P16-093; HBED-CC-PHENOXY-PSMA; PSMA-093; PSMA-93Latest Information Update: 26 Sep 2023
Price :
$50
*
At a glance
- Originator Five Eleven Pharma
- Developer Five Eleven Pharma; Indiana University; Peking Union Medical College Hospital
- Class Radiopharmaceutical diagnostics
- Mechanism of Action Emission-computed tomography enhancers; Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Prostate cancer
- Phase I/II Glioma; Renal cancer
Most Recent Events
- 22 Sep 2023 Five Eleven Pharma in collaboration with Peking Union Medical College Hospital plans a phase I/II trial for Sjogren's syndrome (Diagnosis) in October 2023 (IV) (NCT06049368)
- 15 Sep 2022 Peking Union Medical College Hospital completes a phase I/II trial in Renal cancer (Diagnosis) in China (IV) (NCT05432947)
- 18 Apr 2022 Phase-I clinical trials in Renal cancer and Prostate cancer (Diagnosis, Metastatic disease) is ongoing in USA (IV) (NCT03073395)